Semax
A synthetic heptapeptide derived from the N-terminal fragment of ACTH(4-10) with a Pro-Gly-Pro C-terminal extension conferring resistance to enzymatic degradation. Research has documented BDNF and NGF upregulation, improved cognitive performance metrics, and neuroprotective effects in ischemia models.
Research Use Only. Semax is sold exclusively for in vitro research and laboratory use by qualified scientists. Not for human consumption, veterinary use, or clinical administration.
Research Literature
Published Research
Semax is an ACTH-derived neuropeptide documented for BDNF/NGF upregulation, cognitive enhancement, and neuroprotection in ischemia models.
Semax increases BDNF and NGF in the brain
Key finding: Semax significantly elevates BDNF and NGF levels in hippocampus and cortex, supporting neuroplasticity research applications.
PubMed 24793550 ↗Neuroprotective effects of Semax in ischemia models
Key finding: Semax reduces infarct volume and improves neurological outcomes in experimental stroke models.
PubMed 18602718 ↗Cognitive enhancement by Semax in animal studies
Key finding: Semax improves learning and memory performance metrics across multiple cognitive testing paradigms.
PubMed 22715374 ↗Same Category